Total Assets
Stockholders' Equity
Cash & Equivalents
Long-Term Debt
Revenue trend
Balance Sheet
Income Statement
Per Share & Cash Flow
Insider activity
SEC fundamentals · as filed in 10-K FY2025, period ended Dec 31, 2025 · updated Aug 29, 2026
as filed in 10-K FY2025, period ended Dec 31, 2025 · View filings on EDGAR ↗
In its FY2025 report, Lyra Therapeutics, Inc. reported total assets of $36.1M, stockholders' equity of -$10.7M, and revenue of $398,000. Every figure below is taken directly from Lyra Therapeutics, Inc.'s SEC filings: each links to the source document on EDGAR.
Revenue · FY2021–FY2025 · as reported
as of Dec 31, 2025 · 10-K
10-K (annual) · period ended Dec 31, 2025
10-K (annual) · period ended Dec 31, 2025
| EPS (diluted) | $-18.62 | Earnings | source ↗ |
| EPS (basic) | $-18.62 | Earnings | source ↗ |
| Shares Outstanding | 1.8M | Entity | source ↗ |
| Cash from Operations | -$28.9M | Net | source ↗ |
| Cash from Financing | $4.3M | Net | source ↗ |
| Cash from Investing | -$98,000 | Net | source ↗ |
Form 4 open-market activity, last 180 days
No open-market Form 4 transactions filed in the last 180 days.
No material restatements detected across 163annual fact-keys: this company's as-filed numbers have held between filings. Point-in-time and as-of history are available via the API.
As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail behind the counts above, plus MCP access for your own agents, across the whole SEC universe.
Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.